Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
What findings does the ECG demonstrate?
The ECG demonstrates features suggestive of an accessory pathway. Evidence of an accessory pathway can be present in up to 0.3% of individuals during routine ECG, the great majority being asymptomatic. Although they have been associated with sudden cardiac death in both athletic and non-athletic individuals, they are not inherited in the great majority of cases. In this particular case electrophysiological studies identified a slow conducting accessory pathway in the right free wall.The presence of anterior T-wave inversions with convex ST-segment elevation is present in 12% of Afro-Caribbean athletes and is considered a manifestation of ethnic variation to physiological adaptation to exercise. In the presence of symptoms or family history of cardiomyopathy or sudden cardiac death however, all athletes should undergo comprehensive clinical evaluation to exclude quiescent cardiomyopathy and in particular ARVC.In this case given the family history both the athlete and all his 1st-degree family relatives were comprehensively evaluated. The mother also exhibited T-wave inversions in the anterior leads. Subsequent gene testing confirmed the presence of a pathogenic desmosomal protein mutation in both the athlete and his mother, most likely accounting for the sudden cardiac death.Based on a clinical diagnosis of ARVC, confirmed by genetic testing, the athlete would not be eligible for formal competition, according to the ESC recommendations*.Further treatment is dictated by the presence of arrhythmia and associated haemodynamic compromise. High risk individuals such as individuals with prior cardiac arrest, episodes ventricular tachycardia with haemodynamic compromise (syncope) should be offered an implantable cardioverter defibrillator (ICD).Voltage criterion for left ventricular hypertrophy is common in athletes and in isolation it is rarely associated with underlying disease.Finally, early repolarisation patterns are common in athletes and do not indicate pathology, particularly when associated with an up-sloping ST-segment.
Access the ESC e-learning platform and discover the EAPC Sports Cardiology online courses. Not yet an EAPC member?
Pelliccia A et al. Recommendations for competitive sports participation in athletes with cardiovascular disease. A conscensus document from the study group of sports cardiology of the working group of cardiac rehabilitation and exercise physiology and the working group of myocardial and pericardial diseases of the European society of cardiology. Eur Heart J 2005;26:1422-1445
Dr Aneil Malhotra, Cardiology research fellowDr Michael Papadakis, Lecturer in cardiology, St George’s university of LondonProf Sanjay Sharma, Professor of clinical cardiology, St George’s university of London
© 2017 European Society of Cardiology. All rights reserved